{"id":60915,"date":"2026-03-24T14:14:17","date_gmt":"2026-03-24T06:14:17","guid":{"rendered":"https:\/\/flcube.com\/?p=60915"},"modified":"2026-03-24T14:14:18","modified_gmt":"2026-03-24T06:14:18","slug":"insilico-medicine-partners-with-aska-pharma-ai-driven-target-discovery-collaboration-targets-gynecological-diseases","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=60915","title":{"rendered":"Insilico Medicine Partners with ASKA Pharma \u2013 AI\u2011Driven Target Discovery Collaboration Targets Gynecological Diseases"},"content":{"rendered":"\n<p><strong>Insilico Medicine<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/3696:HKG\">HKG: 3696<\/a>) announced a <strong>strategic drug discovery collaboration<\/strong> with <strong>ASKA Pharmaceutical Co., Ltd.<\/strong>, a <strong>Japanese pharmaceutical company<\/strong> specializing in <strong>internal medicine, obstetrics, and gynecology<\/strong>, to leverage Insilico&#8217;s <strong>proprietary AI\u2011driven target discovery engine, PandaOmics<\/strong>, for identifying <strong>innovative therapeutic targets<\/strong> in <strong>challenging gynecological diseases<\/strong> \u2013 including <strong>endometriosis, uterine fibroids, and adenomyosis<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-overview\">Partnership Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>Insilico Medicine (HKG: 3696) + ASKA Pharmaceutical Co., Ltd. (Japan)<\/td><\/tr><tr><td><strong>Collaboration Type<\/strong><\/td><td>Strategic drug discovery partnership<\/td><\/tr><tr><td><strong>Technology Platform<\/strong><\/td><td><strong>PandaOmics<\/strong> \u2013 Insilico&#8217;s AI\u2011driven target discovery engine<\/td><\/tr><tr><td><strong>Therapeutic Focus<\/strong><\/td><td>Gynecological diseases: <strong>endometriosis, uterine fibroids, adenomyosis<\/strong><\/td><\/tr><tr><td><strong>Geographic Scope<\/strong><\/td><td>Global target discovery; ASKA retains development\/commercialization rights<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-collaboration-structure-amp-responsibilities\">Collaboration Structure &amp; Responsibilities<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Partner<\/th><th>Role<\/th><th>Strategic Value<\/th><\/tr><\/thead><tbody><tr><td><strong>Insilico Medicine<\/strong><\/td><td><strong>AI\u2011powered target discovery<\/strong> \u2013 disease hypothesis generation via PandaOmics<\/td><td>Accelerated target identification; reduced discovery timeline; novel biology insights<\/td><\/tr><tr><td><strong>ASKA Pharmaceutical<\/strong><\/td><td><strong>Target validation<\/strong> \u2013 druggability assessment and experimental validation of AI\u2011predicted targets<\/td><td>Established gynecology expertise; clinical development infrastructure; Japan market access<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-target-disease-areas-amp-unmet-need\">Target Disease Areas &amp; Unmet Need<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Disease<\/th><th>Prevalence \/ Market Context<\/th><th>AI\u2011Discovery Opportunity<\/th><\/tr><\/thead><tbody><tr><td><strong>Endometriosis<\/strong><\/td><td>Affects <strong>10% of reproductive\u2011age women<\/strong> globally; limited non\u2011hormonal therapies; significant pain\/morbidity<\/td><td>Novel target mechanisms beyond estrogen pathway; precision medicine approaches<\/td><\/tr><tr><td><strong>Uterine Fibroids (Leiomyomas)<\/strong><\/td><td><strong>70\u201180% of women<\/strong> by age 50; leading cause of hysterectomy; GnRH agonists have limitations<\/td><td>Non\u2011hormonal, fertility\u2011sparing therapeutic targets<\/td><\/tr><tr><td><strong>Adenomyosis<\/strong><\/td><td><strong>20\u201135% of women<\/strong>; often co\u2011occurs with endometriosis; limited approved therapies<\/td><td>Distinct pathophysiology from endometriosis; targeted therapy potential<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications-amp-market-context\">Strategic Implications &amp; Market Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>AI\u2011Driven Drug Discovery Trend:<\/strong> Global AI\u2011pharma partnerships exceeded <strong>US$5 billion<\/strong> in 2024\u20112025; PandaOmics validated by <strong>previous collaborations<\/strong> (Fosun, Janssen, Sanofi); <strong>target discovery\u2011focused deals<\/strong> (vs. full development partnerships) reflect risk\u2011sharing model for early\u2011stage innovation.<\/li>\n\n\n\n<li><strong>Insilico Platform Validation:<\/strong> ASKA partnership follows <strong>ISM001\u2011055 (fibrosis) Phase II success<\/strong> and <strong>ISM9686 (oncology) IND approvals<\/strong>; PandaOmics application to <strong>gynecology<\/strong> expands platform <strong>therapeutic area diversity<\/strong>; Japanese pharma validation enhances <strong>Asia\u2011Pacific credibility<\/strong>.<\/li>\n\n\n\n<li><strong>ASKA Strategic Rationale:<\/strong> Mid\u2011size Japanese pharma (<strong>~US$500 million<\/strong> annual revenue) gains <strong>AI\u2011enabled innovation access<\/strong> without internal platform investment; gynecology focus aligns with <strong>established therapeutic expertise<\/strong>; potential for <strong>first\u2011in\u2011class mechanisms<\/strong> in underserved women&#8217;s health indications.<\/li>\n\n\n\n<li><strong>Women&#8217;s Health Market Dynamics:<\/strong> Global gynecology therapeutics <strong>US$15\u201120 billion<\/strong> annually; endometriosis segment <strong>US$2\u20113 billion<\/strong> with &lt;30% patient satisfaction with current hormonal therapies; <strong>non\u2011hormonal innovation<\/strong> represents major commercial opportunity; AI\u2011discovered targets may enable <strong>precision medicine<\/strong> approaches vs. one\u2011size\u2011fits\u2011all hormonal suppression.<\/li>\n\n\n\n<li><strong>Partnership Financial Structure:<\/strong> Likely <strong>upfront payment + milestones + royalties<\/strong> on resulting products; Insilico retains <strong>algorithm\/platform IP<\/strong>; ASKA gains <strong>exclusive target\/product rights<\/strong> in gynecology; estimated deal value <strong>US$20\u201150 million<\/strong> upfront with <strong>US$200\u2011400 million<\/strong> total biobucks assuming 2\u20113 programs advance to IND.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding target discovery timelines, validation success rates, and partnership value creation for the Insilico\u2011ASKA collaboration. Actual results may differ due to AI prediction accuracy variability, target druggability challenges, and competitive dynamics in the gynecology therapeutics landscape.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Insilico Medicine (HKG: 3696) announced a strategic drug discovery collaboration with ASKA Pharmaceutical Co., Ltd.,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":60916,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[99,4650,4514,164],"class_list":["post-60915","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-ai","tag-aska-pharmaceutical","tag-hkg-3696","tag-insilico-medicine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Insilico Medicine Partners with ASKA Pharma \u2013 AI\u2011Driven Target Discovery Collaboration Targets Gynecological Diseases - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Insilico Medicine (HKG: 3696) announced a strategic drug discovery collaboration with ASKA Pharmaceutical Co., Ltd., a Japanese pharmaceutical company specializing in internal medicine, obstetrics, and gynecology, to leverage Insilico&#039;s proprietary AI\u2011driven target discovery engine, PandaOmics, for identifying innovative therapeutic targets in challenging gynecological diseases \u2013 including endometriosis, uterine fibroids, and adenomyosis.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=60915\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Insilico Medicine Partners with ASKA Pharma \u2013 AI\u2011Driven Target Discovery Collaboration Targets Gynecological Diseases\" \/>\n<meta property=\"og:description\" content=\"Insilico Medicine (HKG: 3696) announced a strategic drug discovery collaboration with ASKA Pharmaceutical Co., Ltd., a Japanese pharmaceutical company specializing in internal medicine, obstetrics, and gynecology, to leverage Insilico&#039;s proprietary AI\u2011driven target discovery engine, PandaOmics, for identifying innovative therapeutic targets in challenging gynecological diseases \u2013 including endometriosis, uterine fibroids, and adenomyosis.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=60915\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-24T06:14:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-24T06:14:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2406.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60915#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60915\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Insilico Medicine Partners with ASKA Pharma \u2013 AI\u2011Driven Target Discovery Collaboration Targets Gynecological Diseases\",\"datePublished\":\"2026-03-24T06:14:17+00:00\",\"dateModified\":\"2026-03-24T06:14:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60915\"},\"wordCount\":485,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60915#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2406.webp\",\"keywords\":[\"AI\",\"ASKA Pharmaceutical\",\"HKG: 3696\",\"Insilico Medicine\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=60915#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60915\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=60915\",\"name\":\"Insilico Medicine Partners with ASKA Pharma \u2013 AI\u2011Driven Target Discovery Collaboration Targets Gynecological Diseases - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60915#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60915#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2406.webp\",\"datePublished\":\"2026-03-24T06:14:17+00:00\",\"dateModified\":\"2026-03-24T06:14:18+00:00\",\"description\":\"Insilico Medicine (HKG: 3696) announced a strategic drug discovery collaboration with ASKA Pharmaceutical Co., Ltd., a Japanese pharmaceutical company specializing in internal medicine, obstetrics, and gynecology, to leverage Insilico's proprietary AI\u2011driven target discovery engine, PandaOmics, for identifying innovative therapeutic targets in challenging gynecological diseases \u2013 including endometriosis, uterine fibroids, and adenomyosis.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60915#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=60915\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60915#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2406.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2406.webp\",\"width\":1080,\"height\":608,\"caption\":\"Insilico Medicine Partners with ASKA Pharma \u2013 AI\u2011Driven Target Discovery Collaboration Targets Gynecological Diseases\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60915#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Insilico Medicine Partners with ASKA Pharma \u2013 AI\u2011Driven Target Discovery Collaboration Targets Gynecological Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Insilico Medicine Partners with ASKA Pharma \u2013 AI\u2011Driven Target Discovery Collaboration Targets Gynecological Diseases - Insight, China&#039;s Pharmaceutical Industry","description":"Insilico Medicine (HKG: 3696) announced a strategic drug discovery collaboration with ASKA Pharmaceutical Co., Ltd., a Japanese pharmaceutical company specializing in internal medicine, obstetrics, and gynecology, to leverage Insilico's proprietary AI\u2011driven target discovery engine, PandaOmics, for identifying innovative therapeutic targets in challenging gynecological diseases \u2013 including endometriosis, uterine fibroids, and adenomyosis.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=60915","og_locale":"en_US","og_type":"article","og_title":"Insilico Medicine Partners with ASKA Pharma \u2013 AI\u2011Driven Target Discovery Collaboration Targets Gynecological Diseases","og_description":"Insilico Medicine (HKG: 3696) announced a strategic drug discovery collaboration with ASKA Pharmaceutical Co., Ltd., a Japanese pharmaceutical company specializing in internal medicine, obstetrics, and gynecology, to leverage Insilico's proprietary AI\u2011driven target discovery engine, PandaOmics, for identifying innovative therapeutic targets in challenging gynecological diseases \u2013 including endometriosis, uterine fibroids, and adenomyosis.","og_url":"https:\/\/flcube.com\/?p=60915","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-24T06:14:17+00:00","article_modified_time":"2026-03-24T06:14:18+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2406.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=60915#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=60915"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Insilico Medicine Partners with ASKA Pharma \u2013 AI\u2011Driven Target Discovery Collaboration Targets Gynecological Diseases","datePublished":"2026-03-24T06:14:17+00:00","dateModified":"2026-03-24T06:14:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=60915"},"wordCount":485,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=60915#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2406.webp","keywords":["AI","ASKA Pharmaceutical","HKG: 3696","Insilico Medicine"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=60915#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=60915","url":"https:\/\/flcube.com\/?p=60915","name":"Insilico Medicine Partners with ASKA Pharma \u2013 AI\u2011Driven Target Discovery Collaboration Targets Gynecological Diseases - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=60915#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=60915#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2406.webp","datePublished":"2026-03-24T06:14:17+00:00","dateModified":"2026-03-24T06:14:18+00:00","description":"Insilico Medicine (HKG: 3696) announced a strategic drug discovery collaboration with ASKA Pharmaceutical Co., Ltd., a Japanese pharmaceutical company specializing in internal medicine, obstetrics, and gynecology, to leverage Insilico's proprietary AI\u2011driven target discovery engine, PandaOmics, for identifying innovative therapeutic targets in challenging gynecological diseases \u2013 including endometriosis, uterine fibroids, and adenomyosis.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=60915#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=60915"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=60915#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2406.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2406.webp","width":1080,"height":608,"caption":"Insilico Medicine Partners with ASKA Pharma \u2013 AI\u2011Driven Target Discovery Collaboration Targets Gynecological Diseases"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=60915#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Insilico Medicine Partners with ASKA Pharma \u2013 AI\u2011Driven Target Discovery Collaboration Targets Gynecological Diseases"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2406.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60915","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=60915"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60915\/revisions"}],"predecessor-version":[{"id":60917,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60915\/revisions\/60917"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/60916"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=60915"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=60915"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=60915"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}